<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34158851</PMID><DateCompleted><Year>2021</Year><Month>07</Month><Day>29</Day></DateCompleted><DateRevised><Year>2021</Year><Month>07</Month><Day>29</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1838-7640</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>15</Issue><PubDate><Year>2021</Year></PubDate></JournalIssue><Title>Theranostics</Title><ISOAbbreviation>Theranostics</ISOAbbreviation></Journal><ArticleTitle>R13 preserves motor performance in SOD1<sup>G93A</sup> mice by improving mitochondrial function.</ArticleTitle><Pagination><StartPage>7294</StartPage><EndPage>7307</EndPage><MedlinePgn>7294-7307</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.7150/thno.56070</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease characterized by death of motor neurons in the brain and spinal cord. However, so far, there is no effective treatment for ALS. <b>Methods:</b> In this study, R13, a prodrug of 7,8-dihydroxyflavone, selectively activating tyrosine kinase receptor B (TrkB) signaling pathway, was administered prophylactically to 40-day old SOD1<sup>G93A</sup> mice for 90 days. The motor performance was investigated by rotarod test, climbing-pole test, grip strength test and hanging endurance test. Afterwards, the spinal cord and medulla oblongata of 130-day old mice were harvested, and the proteomics revealed the effect of R13 on mouse protein expression profile. Astrocytes and microglial proliferation were assessed by immunohistochemical analysis. The number of motor neurons in the spinal cord is determined by Nissl staining. The effect of R13 on gastrocnemius morphology was assessed by HE staining. The effect of R13 on the survival rate was accomplished with worms stably expressing G93A SOD1. <b>Results:</b> Behavioral tests showed that R13 significantly attenuated abnormal motor performance of SOD1<sup>G93A</sup> mice. R13 reduced the advance of spinal motor neuron pathology and gastrocnemius muscle atrophy. The proliferation of microglia and astrocytes was reduced by R13 treatment. Mitochondriomics analysis revealed that R13 modified the mitochondrial protein expression profiles in the medulla oblongata and spinal cord of SOD1<sup>G93A</sup> mice, particularly promoting the expression of proteins related to oxidative phosphorylation (OXPHOS). Further study found that R13 activated AMPK/PGC-1&#x3b1;/Nrf1/Tfam, promoted mitochondrial biogenesis and ameliorated mitochondrial dysfunction. Lastly, R13 prolonged the survival rate of worms stably expressing G93A SOD1. <b>Conclusions:</b> These findings suggest oral R13 treatment slowed the advance of motor system disease in a reliable animal model of ALS, supporting that R13 might be useful for treating ALS.</AbstractText><CopyrightInformation>&#xa9; The author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xiao</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Key Laboratory of Modern Toxicology of Shenzhen, Shenzhen Medical Key Subject of Modern Toxicology, Shenzhen Center for Disease Control and Prevention, Shenzhen, 518055, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathophysiology, School of Basic Medicine and the Collaborative Innovation Center for Brain Science, Key Laboratory of Ministry of Education of China and Hubei Province for Neurological Disorders, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Chongyang</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Pathophysiology, School of Basic Medicine and the Collaborative Innovation Center for Brain Science, Key Laboratory of Ministry of Education of China and Hubei Province for Neurological Disorders, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhan</LastName><ForeName>Xu</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Pathophysiology, School of Basic Medicine and the Collaborative Innovation Center for Brain Science, Key Laboratory of Ministry of Education of China and Hubei Province for Neurological Disorders, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Binyao</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Tianjin Institute of Pharmaceutical Research New Drug Assessment Co. Ltd, Tianjin 300301, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Zaijun</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Institute of New Drug Research and Guangzhou, Key Laboratory of Innovative Chemical Drug Research in Cardio-Cerebrovascular Diseases, Jinan University College of Pharmacy, Guangzhou 510632, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Shupeng</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>School of Chemical Biology and Biotechnology, Peking University Shenzhen Graduate School, Shenzhen, 518055, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xie</LastName><ForeName>Yongmei</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, and Collaborative Innovation Center for Biotherapy, Sichuan University, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Xiangrong</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Critical Care Medicine, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shen</LastName><ForeName>Yuanyuan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>National-Regional Key Technology Engineering Laboratory for Medical Ultrasound, School of Biomedical Engineering, Health Science Center, Shenzhen University, Shenzhen, 518060, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Jianjun</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Key Laboratory of Modern Toxicology of Shenzhen, Shenzhen Medical Key Subject of Modern Toxicology, Shenzhen Center for Disease Control and Prevention, Shenzhen, 518055, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Ping</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Pathophysiology, School of Basic Medicine and the Collaborative Innovation Center for Brain Science, Key Laboratory of Ministry of Education of China and Hubei Province for Neurological Disorders, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Gong-Ping</ForeName><Initials>GP</Initials><AffiliationInfo><Affiliation>Department of Pathophysiology, School of Basic Medicine and the Collaborative Innovation Center for Brain Science, Key Laboratory of Ministry of Education of China and Hubei Province for Neurological Disorders, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Co-innovation Center of Neuroregeneration, Nantong University, Nantong, JS, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Xifei</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Key Laboratory of Modern Toxicology of Shenzhen, Shenzhen Medical Key Subject of Modern Toxicology, Shenzhen Center for Disease Control and Prevention, Shenzhen, 518055, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>05</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>Australia</Country><MedlineTA>Theranostics</MedlineTA><NlmUniqueID>101552395</NlmUniqueID><ISSNLinking>1838-7640</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D047309">Flavones</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000606290">SOD1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="C109415">SOD1 G93A protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D013482">Superoxide Dismutase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002490" MajorTopicYN="N">Central Nervous System</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D047309" MajorTopicYN="N">Flavones</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008928" MajorTopicYN="Y">Mitochondria</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009043" MajorTopicYN="Y">Motor Activity</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013482" MajorTopicYN="Y">Superoxide Dismutase</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="Y">Superoxide Dismutase-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">7,8-dihydroxyflavone</Keyword><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Mitochondria</Keyword><Keyword MajorTopicYN="N">Mitochondriomics</Keyword><Keyword MajorTopicYN="N">Motor performance</Keyword></KeywordList><CoiStatement>Competing Interests: The authors have declared that no competing interest exists.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>11</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>5</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>6</Month><Day>23</Day><Hour>7</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>6</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>7</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34158851</ArticleId><ArticleId IdType="pmc">PMC8210609</ArticleId><ArticleId IdType="doi">10.7150/thno.56070</ArticleId><ArticleId IdType="pii">thnov11p7294</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kiernan MC, Vucic S, Cheah BC, Turner MR, Eisen A, Hardiman O. et al. Amyotrophic lateral sclerosis. Lancet. 2011;377:942&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">21296405</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferraiuolo L, Kirby J, Grierson AJ, Sendtner M, Shaw PJ. Molecular pathways of motor neuron injury in amyotrophic lateral sclerosis. Nat Rev Neurol. 2011;7:616&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">22051914</ArticleId></ArticleIdList></Reference><Reference><Citation>Prasad A, Bharathi V, Sivalingam V, Girdhar A, Patel BK. Molecular Mechanisms of TDP-43 Misfolding and Pathology in Amyotrophic Lateral Sclerosis. Front Mol Neurosci. 2019;12:25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6382748</ArticleId><ArticleId IdType="pubmed">30837838</ArticleId></ArticleIdList></Reference><Reference><Citation>Tesla R, Wolf HP, Xu P, Drawbridge J, Estill SJ, Huntington P. et al. Neuroprotective efficacy of aminopropyl carbazoles in a mouse model of amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A. 2012;109:17016&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3479516</ArticleId><ArticleId IdType="pubmed">23027932</ArticleId></ArticleIdList></Reference><Reference><Citation>Savelieff MG, Nam G, Kang J, Lee HJ, Lee M, Lim MH. Development of Multifunctional Molecules as Potential Therapeutic Candidates for Alzheimer's Disease, Parkinson's Disease, and Amyotrophic Lateral Sclerosis in the Last Decade. Chem Rev. 2019;119:1221&#x2013;322.</Citation><ArticleIdList><ArticleId IdType="pubmed">30095897</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuccato C, Cattaneo E. Brain-derived neurotrophic factor in neurodegenerative diseases. Nat Rev Neurol. 2009;5:311&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">19498435</ArticleId></ArticleIdList></Reference><Reference><Citation>Gould TW, Oppenheim RW. Motor neuron trophic factors: therapeutic use in ALS? Brain Res Rev. 2011;67:1&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3109102</ArticleId><ArticleId IdType="pubmed">20971133</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuen EC. The role of neurotrophic factors in disorders of peripheral nerves and motor neurons. Phys Med Rehabil Clin N Am. 2001;12:293&#x2013;306. viii.</Citation><ArticleIdList><ArticleId IdType="pubmed">11345008</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan Q, Elliott J, Snider WD. Brain-derived neurotrophic factor rescues spinal motor neurons from axotomy-induced cell death. Nature. 1992;360:753&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">1281520</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikeda K, Klinkosz B, Greene T, Cedarbaum JM, Wong V, Lindsay RM. et al. Effects of brain-derived neurotrophic factor on motor dysfunction in wobbler mouse motor neuron disease. Ann Neurol. 1995;37:505&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">7717687</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo W, Pang K, Chen Y, Wang S, Li H, Xu Y. et al. TrkB agonistic antibodies superior to BDNF: Utility in treating motoneuron degeneration. Neurobiol Dis. 2019;132:104590.</Citation><ArticleIdList><ArticleId IdType="pubmed">31470106</ArticleId></ArticleIdList></Reference><Reference><Citation>Longo FM, Massa SM. Small-molecule modulation of neurotrophin receptors: a strategy for the treatment of neurological disease. Nat Rev Drug Discov. 2013;12:507&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">23977697</ArticleId></ArticleIdList></Reference><Reference><Citation>Giehl KM, Tetzlaff W. BDNF and NT-3, but not NGF, prevent axotomy-induced death of rat corticospinal neurons in vivo. Eur J Neurosci. 1996;8:1167&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pubmed">8752586</ArticleId></ArticleIdList></Reference><Reference><Citation>Kishino A, Ishige Y, Tatsuno T, Nakayama C, Noguchi H. BDNF prevents and reverses adult rat motor neuron degeneration and induces axonal outgrowth. Exp Neurol. 1997;144:273&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">9168829</ArticleId></ArticleIdList></Reference><Reference><Citation>Mutoh T, Sobue G, Hamano T, Kuriyama M, Hirayama M, Yamamoto M. et al. Decreased phosphorylation levels of TrkB neurotrophin receptor in the spinal cords from patients with amyotrophic lateral sclerosis. Neurochem Res. 2000;25:239&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">10786708</ArticleId></ArticleIdList></Reference><Reference><Citation>A controlled trial of recombinant methionyl human BDNF in ALS. The BDNF Study Group (Phase III) Neurology. 1999;52:1427&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">10227630</ArticleId></ArticleIdList></Reference><Reference><Citation>Jang SW, Liu X, Yepes M, Shepherd KR, Miller GW, Liu Y. et al. A selective TrkB agonist with potent neurotrophic activities by 7,8-dihydroxyflavone. Proc Natl Acad Sci U S A. 2010;107:2687&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2823863</ArticleId><ArticleId IdType="pubmed">20133810</ArticleId></ArticleIdList></Reference><Reference><Citation>Devi L, Ohno M. 7,8-dihydroxyflavone, a small-molecule TrkB agonist, reverses memory deficits and BACE1 elevation in a mouse model of Alzheimer's disease. Neuropsychopharmacology. 2012;37:434&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3242305</ArticleId><ArticleId IdType="pubmed">21900882</ArticleId></ArticleIdList></Reference><Reference><Citation>Castello NA, Nguyen MH, Tran JD, Cheng D, Green KN, LaFerla FM. 7,8-Dihydroxyflavone, a small molecule TrkB agonist, improves spatial memory and increases thin spine density in a mouse model of Alzheimer disease-like neuronal loss. PLoS One. 2014;9:e91453.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3948846</ArticleId><ArticleId IdType="pubmed">24614170</ArticleId></ArticleIdList></Reference><Reference><Citation>Andero R, Heldt SA, Ye K, Liu X, Armario A, Ressler KJ. Effect of 7,8-dihydroxyflavone, a small-molecule TrkB agonist, on emotional learning. Am J Psychiatry. 2011;168:163&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3770732</ArticleId><ArticleId IdType="pubmed">21123312</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu X, Chan CB, Jang SW, Pradoldej S, Huang J, He K. et al. A synthetic 7,8-dihydroxyflavone derivative promotes neurogenesis and exhibits potent antidepressant effect. J Med Chem. 2010;53:8274&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3150605</ArticleId><ArticleId IdType="pubmed">21073191</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai T, Klausmeyer A, Conrad R, Gottschling C, Leo M, Faissner A. et al. 7,8-Dihydroxyflavone leads to survival of cultured embryonic motoneurons by activating intracellular signaling pathways. Mol Cell Neurosci. 2013;56:18&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pubmed">23500004</ArticleId></ArticleIdList></Reference><Reference><Citation>Korkmaz OT, Aytan N, Carreras I, Choi JK, Kowall NW, Jenkins BG. et al. 7,8-Dihydroxyflavone improves motor performance and enhances lower motor neuronal survival in a mouse model of amyotrophic lateral sclerosis. Neurosci Lett. 2014;566:286&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5906793</ArticleId><ArticleId IdType="pubmed">24637017</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C, Wang Z, Zhang Z, Liu X, Kang SS, Zhang Y. et al. The prodrug of 7,8-dihydroxyflavone development and therapeutic efficacy for treating Alzheimer's disease. Proc Natl Acad Sci U S A. 2018;115:578&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5777001</ArticleId><ArticleId IdType="pubmed">29295929</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrazzo S, Gunduz-Cinar O, Stefanova N, Pollack GA, Holmes A, Schmuckermair C. et al. Increased anxiety-like behavior following circuit-specific catecholamine denervation in mice. Neurobiol Dis. 2019;125:55&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6420211</ArticleId><ArticleId IdType="pubmed">30677495</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C, Jiang X, Li Y, Yu H, Li S, Zhang Z. et al. Low-dose oral copper treatment changes the hippocampal phosphoproteomic profile and perturbs mitochondrial function in a mouse model of Alzheimer's disease. Free Radic Biol Med. 2019;135:144&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">30862541</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludolph AC, Bendotti C, Blaugrund E, Hengerer B, Loffler JP, Martin J. et al. Guidelines for the preclinical in vivo evaluation of pharmacological active drugs for ALS/MND: report on the 142nd ENMC international workshop. Amyotroph Lateral Scler. 2007;8:217&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">17653919</ArticleId></ArticleIdList></Reference><Reference><Citation>Carter RJ, Morton J, Dunnett SB. Motor coordination and balance in rodents. Curr Protoc Neurosci. 2001. Chapter 8: Unit 8 12.</Citation><ArticleIdList><ArticleId IdType="pubmed">18428540</ArticleId></ArticleIdList></Reference><Reference><Citation>Kennel P, Revah F, Bohme GA, Bejuit R, Gallix P, Stutzmann JM. et al. Riluzole prolongs survival and delays muscle strength deterioration in mice with progressive motor neuronopathy (pmn) J Neurol Sci. 2000;180:55&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">11090865</ArticleId></ArticleIdList></Reference><Reference><Citation>Ni HM, Williams JA, Ding WX. Mitochondrial dynamics and mitochondrial quality control. Redox Biol. 2015;4:6&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4309858</ArticleId><ArticleId IdType="pubmed">25479550</ArticleId></ArticleIdList></Reference><Reference><Citation>Haidet-Phillips AM, Hester ME, Miranda CJ, Meyer K, Braun L, Frakes A. et al. Astrocytes from familial and sporadic ALS patients are toxic to motor neurons. Nat Biotechnol. 2011;29:824&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3170425</ArticleId><ArticleId IdType="pubmed">21832997</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall ED, Oostveen JA, Gurney ME. Relationship of microglial and astrocytic activation to disease onset and progression in a transgenic model of familial ALS. Glia. 1998;23:249&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">9633809</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikonomidou C, Qin Qin Y, Labruyere J, Olney JW. Motor neuron degeneration induced by excitotoxin agonists has features in common with those seen in the SOD-1 transgenic mouse model of amyotrophic lateral sclerosis. J Neuropathol Exp Neurol. 1996;55:211&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">8786380</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaarsma D, Rognoni F, van Duijn W, Verspaget HW, Haasdijk ED, Holstege JC. CuZn superoxide dismutase (SOD1) accumulates in vacuolated mitochondria in transgenic mice expressing amyotrophic lateral sclerosis-linked SOD1 mutations. Acta Neuropathol. 2001;102:293&#x2013;305.</Citation><ArticleIdList><ArticleId IdType="pubmed">11603803</ArticleId></ArticleIdList></Reference><Reference><Citation>Vande Velde C, McDonald KK, Boukhedimi Y, McAlonis-Downes M, Lobsiger CS, Bel Hadj S. et al. Misfolded SOD1 associated with motor neuron mitochondria alters mitochondrial shape and distribution prior to clinical onset. PLoS One. 2011;6:e22031.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3136936</ArticleId><ArticleId IdType="pubmed">21779368</ArticleId></ArticleIdList></Reference><Reference><Citation>Sorrentino V, Menzies KJ, Auwerx J. Repairing Mitochondrial Dysfunction in Disease. Annu Rev Pharmacol Toxicol. 2018;58:353&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="pubmed">28961065</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanuza MA, Just-Borras L, Hurtado E, Cilleros-Mane V, Tomas M, Garcia N, The Impact of Kinases in Amyotrophic Lateral Sclerosis at the Neuromuscular Synapse: Insights into BDNF/TrkB and PKC Signaling. Cells. 2019. 8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6953086</ArticleId><ArticleId IdType="pubmed">31817487</ArticleId></ArticleIdList></Reference><Reference><Citation>Just-Borras L, Hurtado E, Cilleros-Mane V, Biondi O, Charbonnier F, Tomas M. et al. Running and swimming prevent the deregulation of the BDNF/TrkB neurotrophic signalling at the neuromuscular junction in mice with amyotrophic lateral sclerosis. Cell Mol Life Sci. 2020;77:3027&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">31646358</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogborn DI, Gardiner PF. Effects of exercise and muscle type on BDNF, NT-4/5, and TrKB expression in skeletal muscle. Muscle Nerve. 2010;41:385&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">19813200</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng N, Huke S, Zhu G, Tocchetti CG, Shi S, Aiba T. et al. Constitutive BDNF/TrkB signaling is required for normal cardiac contraction and relaxation. Proc Natl Acad Sci U S A. 2015;112:1880&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4330748</ArticleId><ArticleId IdType="pubmed">25583515</ArticleId></ArticleIdList></Reference><Reference><Citation>Harland M, Torres S, Liu J, Wang X. Neuronal Mitochondria Modulation of LPS-Induced Neuroinflammation. J Neurosci. 2020;40:1756&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7046320</ArticleId><ArticleId IdType="pubmed">31937559</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo H, Xiang Y, Qu X, Liu H, Liu C, Li G. et al. Apelin-13 Suppresses Neuroinflammation Against Cognitive Deficit in a Streptozotocin-Induced Rat Model of Alzheimer's Disease Through Activation of BDNF-TrkB Signaling Pathway. Front Pharmacol. 2019;10:395.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6477031</ArticleId><ArticleId IdType="pubmed">31040784</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang DP, Yin H, Lin Q, Fang SP, Shen JH, Wu YF. et al. Andrographolide enhances hippocampal BDNF signaling and suppresses neuronal apoptosis, astroglial activation, neuroinflammation, and spatial memory deficits in a rat model of chronic cerebral hypoperfusion. Naunyn Schmiedebergs Arch Pharmacol. 2019;392:1277&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">31187188</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen J, Li S, Zheng C, Wang F, Luo Y, Wu L. et al. Tetramethylpyrazine nitrone improves motor dysfunction and pathological manifestations by activating the PGC-1alpha/Nrf2/HO-1 pathway in ALS mice. Neuropharmacology. 2021;182:108380.</Citation><ArticleIdList><ArticleId IdType="pubmed">33152451</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>